Amy L Shafrir1, Megan S Rice2, Mamta Gupta3, Kathryn L Terry4, Bernard A Rosner5, Rulla M Tamimi6, Jonathan L Hecht3, Shelley S Tworoger6. 1. Department of Epidemiology, Harvard TH Chan School of Public Health, 677 Huntington Ave, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA, USA. Electronic address: amy.shafrir@mail.harvard.edu. 2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA, USA; Clinical and Translation Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, USA. 3. Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, Boston, MA, USA. 4. Department of Epidemiology, Harvard TH Chan School of Public Health, 677 Huntington Ave, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School, 221 Longwood Ave, Boston, MA, USA. 5. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA, USA; Department of Biostatistics, Harvard TH Chan School of Public Health, 677 Huntington Ave, Boston, MA, USA. 6. Department of Epidemiology, Harvard TH Chan School of Public Health, 677 Huntington Ave, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA, USA.
Abstract
OBJECTIVE: We assessed the association between reproductive and hormonal factors and ovarian cancer incidence characterized by estrogen receptor-α (ERα) and progesterone receptor (PR) status. METHODS: Tissue microarrays were used to assess ERα and PR expression among 197 Nurses' Health Study (NHS), 42 NHSII and 76 New England Case-Control Study (NECC) ovarian cancer cases. NHS/NHSII cases were matched to up to 4 controls (n=954) on diagnosis date and birth year. NECC controls (n=725) were frequency matched on age. Cases were considered receptor positive if ≥1% of tumor cells stained positive. Associations by ERα and PR status were assessed using polytomous logistic regression. p-Value for heterogeneity was calculated using a likelihood ratio test. RESULTS: 45% of ovarian tumors were PR(+), 78% were ERα(+) and 45% were ERα(+)/PR(+), while 22% were ERα(-)/PR(-). Postmenopausal status was associated with an increased risk of PR(-) tumors (OR: 2.07; 95%CI: 1.15-3.75; p-heterogeneity=0.01) and age at natural menopause was inversely associated with PR(-) tumors (OR, per 5years: 0.77; 95%CI: 0.61-0.96; p-het=0.01). Increasing duration of postmenopause was differentially associated by PR status (p-het=0.0009). Number of children and tubal ligation were more strongly associated with ERα(-) versus ERα(+) tumors (p-het=0.002 and 0.05, respectively). No differential associations were observed for oral contraceptive or hormone therapy use. CONCLUSIONS: Postmenopausal women have an increased risk of developing PR(-) ovarian tumors compared to premenopausal women. The associations observed for ovarian cancer differ from those seen for breast cancer suggesting that the biology for tumor development through ERα and PR pathways may differ.
OBJECTIVE: We assessed the association between reproductive and hormonal factors and ovarian cancer incidence characterized by estrogen receptor-α (ERα) and progesterone receptor (PR) status. METHODS: Tissue microarrays were used to assess ERα and PR expression among 197 Nurses' Health Study (NHS), 42 NHSII and 76 New England Case-Control Study (NECC) ovarian cancer cases. NHS/NHSII cases were matched to up to 4 controls (n=954) on diagnosis date and birth year. NECC controls (n=725) were frequency matched on age. Cases were considered receptor positive if ≥1% of tumor cells stained positive. Associations by ERα and PR status were assessed using polytomous logistic regression. p-Value for heterogeneity was calculated using a likelihood ratio test. RESULTS: 45% of ovarian tumors were PR(+), 78% were ERα(+) and 45% were ERα(+)/PR(+), while 22% were ERα(-)/PR(-). Postmenopausal status was associated with an increased risk of PR(-) tumors (OR: 2.07; 95%CI: 1.15-3.75; p-heterogeneity=0.01) and age at natural menopause was inversely associated with PR(-) tumors (OR, per 5years: 0.77; 95%CI: 0.61-0.96; p-het=0.01). Increasing duration of postmenopause was differentially associated by PR status (p-het=0.0009). Number of children and tubal ligation were more strongly associated with ERα(-) versus ERα(+) tumors (p-het=0.002 and 0.05, respectively). No differential associations were observed for oral contraceptive or hormone therapy use. CONCLUSIONS: Postmenopausal women have an increased risk of developing PR(-) ovarian tumors compared to premenopausal women. The associations observed for ovarian cancer differ from those seen for breast cancer suggesting that the biology for tumor development through ERα and PR pathways may differ.
Authors: Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Patrick M Sluss; Daniel W Cramer Journal: Am J Epidemiol Date: 2005-03-01 Impact factor: 4.897
Authors: Ko-Hui Tung; Marc T Goodman; Anna H Wu; Katharine McDuffie; Lynne R Wilkens; Laurence N Kolonel; Abraham M Y Nomura; Keith Y Terada; Michael E Carney; Leslie H Sobin Journal: Am J Epidemiol Date: 2003-10-01 Impact factor: 4.897
Authors: Weiva Sieh; Shannon Salvador; Valerie McGuire; Rachel Palmieri Weber; Kathryn L Terry; Mary Anne Rossing; Harvey Risch; Anna H Wu; Penelope M Webb; Kirsten Moysich; Jennifer A Doherty; Anna Felberg; Dianne Miller; Susan J Jordan; Marc T Goodman; Galina Lurie; Jenny Chang-Claude; Anja Rudolph; Susanne Krüger Kjær; Allan Jensen; Estrid Høgdall; Elisa V Bandera; Sara H Olson; Melony G King; Lorna Rodriguez-Rodriguez; Lambertus A Kiemeney; Tamara Marees; Leon F Massuger; Anne M van Altena; Roberta B Ness; Daniel W Cramer; Malcolm C Pike; Celeste Leigh Pearce; Andrew Berchuck; Joellen M Schildkraut; Alice S Whittemore Journal: Int J Epidemiol Date: 2013-04 Impact factor: 7.196
Authors: Holly R Harris; Megan S Rice; Amy L Shafrir; Elizabeth M Poole; Mamta Gupta; Jonathan L Hecht; Kathryn L Terry; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-13 Impact factor: 4.254
Authors: Naoko Sasamoto; Paul A Stewart; Tianyi Wang; Sean J Yoder; Srikumar Chellappan; Jonathan L Hecht; Brooke L Fridley; Kathryn L Terry; Shelley S Tworoger Journal: J Ovarian Res Date: 2022-05-13 Impact factor: 5.506
Authors: Naoko Sasamoto; Tianyi Wang; Mary K Townsend; Jonathan L Hecht; A Heather Eliassen; Mingyang Song; Kathryn L Terry; Shelley S Tworoger; Holly R Harris Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-03-02 Impact factor: 4.090
Authors: Marina Dehara; Michael C Sachs; Susanna Kullberg; Johan Grunewald; Anders Blomberg; Elizabeth V Arkema Journal: BMC Pulm Med Date: 2022-01-24 Impact factor: 3.317
Authors: Amy L Shafrir; Ana Babic; Margaret Gates Kuliszewski; Megan S Rice; Mary K Townsend; Jonathan L Hecht; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-08-20 Impact factor: 4.254